ESMO: Bristol Myers axes Immatics' bispecific after $150M bet
WEBSep 16, 2024 · Immatics is the latest partner to get a termination notice, leaving it in full control of a bispecific molecule that BMS picked up for $150 million upfront late in 2021. The deal, which featured ...
Press Releases - Immatics N.V.
WEBJul 31, 2024 · Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024. Houston, Texas and Tuebingen, Germany, July 18, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today …
Moderna and Immatics Announce Strategic Multi-Platform …
WEBSep 11, 2023 · Collaboration to include evaluation of Immatics’ investigational IMA203 PRAME TCR-T in combination with Moderna’s investigational PRAME mRNA cancer vaccine; Immatics to receive $120 million upfront cash payment plus research funding with the potential for additional milestone and royalty payments
News Archives - Immatics
WEBAug 13, 2024 · Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update. by Trophic.
Immatics Presents Clinical Proof-of-Concept Data from Ongoing …
WEBSep 16, 2024 · 1 Patients in this analysis had received IMA401 infusions ≥ 1 mg and showed MAGEA4/8 target expression higher than the MAGEA4/8 high qPCR threshold (n=17).. About IMA401 TCER® IMA401 is Immatics’ most advanced TCER® molecule from the Bispecifics pipeline that targets an HLA-A*02-presented (human leukocyte antigen) peptide derived from two different cancer-associated proteins, melanoma ...
ESMO 2024: BMS cuts ties as Immatics regains full rights to …
WEB6 days ago · Immatics has been left with the full rights to develop a bispecific molecule after its partner Bristol Myers Squibb (BMS) cut ties with the project. BMS has handed back both the development and commercialisation rights for IMA401 to the biopharmaceutical company after a $150m upfront payment in 2021, with an …
Immatics Presents Clinical Proof-of-Concept Data from Ongoing …
WEBSep 16, 2024 · GlobeNewswire Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides ...
Immatics Announces Full Year 2023 Financial Results and …
WEBMar 21, 2024 · In September 2023, Immatics and Moderna announced a strategic multi-platform collaboration to develop innovative oncology therapeutics; Immatics received $120 million upfront payment, and the...
Immatics Announces Proposed Public Offering - Yahoo Finance
WEBJan 17, 2024 · Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T...
Immatics Reports Clinical Responses across Multiple Solid
WEBNov 9, 2021 · In the ongoing ACTengine® IMA203 trial, Immatics is treating advanced solid cancer patients utilizing TCR-T cells directed against an HLA-A*02-presented peptide derived from preferentially...